Medicare对 " 健康卫士 " 癌症监测血液测试的覆盖率上升了21.1%。 Medicare's coverage of Guardant Health's cancer-monitoring blood test sends stock up 21.1%.

在 Medicare 同意支付其用于监测治疗后结直肠癌复发的 Guardant Reveal 测试后，Guardant Health 的股价飙升了 21.1%。 Guardant Health's stock spiked by 21.1% after Medicare agreed to cover their Guardant Reveal test, used to monitor colorectal cancer recurrence post-treatment. 血液测试检测发现肿瘤DNA在循环,有助于在不需要组织样本的情况下进行早期检测。 The blood test detects circulating tumor DNA, aiding in early detection without needing a tissue sample. 预计这种覆盖面的扩大将增加警卫保健在日益增长的癌症血液测试行业的收入和市场存在。 This coverage expansion is expected to boost Guardant Health's revenue and market presence in the growing cancer blood test industry.